 |
News
In the News
Local reporters approach Dr. Hurley for comment on the news about White House Press Secretary Tony Snow’s recent recurrence of cancer.
Colorectal Cancer News
Thu, 08 May 2008 02:00:00 PDT
Dutch Authorize Manufacture Of Vaccinogen's New Anti-Colon Cancer Vaccine; License Clears Path To European Production, Final FDA Trial
Vaccinogen Inc. said Dutch health authorities licensed it to manufacture its break-through OncoVAX anti-colon cancer vaccine, immediately clearing the path to more than US$100 million of potential European sales.The Dutch approval of the company's facility based in Emmen, The Netherlands also paves the way to its pivotal US FDA Phase IIIb clinical trial -- the final step before the vaccine can be sold in the United States.
| Wed, 07 May 2008 02:00:00 PDT
Curis Announces Genentech's Initiation Of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog antagonist, in metastatic colorectal cancer. As a result, Genentech will make a $3 million cash payment to Curis under the companies' June 2003 collaboration agreement.
| Wed, 07 May 2008 00:00:00 PDT
Similar Outcomes For Minimally Invasive, Open Surgery In Colon Cancer
Large, open incisions that cause pain and require lengthy healing times might be unnecessary to treat colorectal cancer patients successfully, according to a new review of studies."For a long time, many surgeons have been afraid that laparoscopy might impair survival in colorectal cancer patients and cause metastases in the skin openings that are used to insert the instruments, but this has proven not to be the case," said lead reviewer Esther Kuhry, M.D.
| Wed, 07 May 2008 00:00:00 PDT
Poniard Pharmaceuticals Completes Enrollment Of Phase 2 Picoplatin Trial In Colorectal Cancer
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating picoplatin combination chemotherapy for the first-line treatment of metastatic colorectal cancer (CRC). Early data from this trial are expected in the second half of 2008.
| Tue, 06 May 2008 05:00:00 PDT
Novel Mechanism For The Development Of Colon Cancer Discovered
Recent work from the Finnish Academy Center of Excellence on Cancer Biology at the University of Helsinki, Finland, has shed light on the mechanisms of colon tumor development and may help to design better treatment for this disease.Colon cancer is one of the most common malignancies in Western countries: both men and women face a lifetime risk of nearly 6% for the development of invasive colorectal cancer.
|
Crohn's Disease News
Thu, 24 Apr 2008 00:00:00 PDT
FDA Approval Of Cimzia(R) For Crohn's Disease Represents Latest Milestone For Nektar's PEGylation Technology Platform
The U.S. Food and Drug Administration (FDA) approved UCB's Cimzia(R) (certolizumab pegol) for reducing the signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy. Cimzia(R) is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA.
| Wed, 23 Apr 2008 10:00:00 PDT
Cimzia® Approved In United States For Crohn's Disease
According to a press release from UCB on April 22, 2008, a newpegylatedanti-TNFα, will be made available in the United States under thename Cimzia® in the next few days. This will be a new,promising option for patients suffering from moderate to severe Crohn'sDisease. Crohn'sDisease (CD) is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.
| Wed, 23 Apr 2008 04:00:00 PDT
FDA Approves Cimzia To Treat Crohn's Disease
A new drug has been approved to help sufferers of Crohn's disease, the U.S. Food and Drug Administration announced today. Cimzia (certolizumab pegol) received approval for adults with moderate to severe Crohn's disease who have not responded to conventional therapies. This product was approved with a Medication Guide.Crohn's disease is a chronic, inflammatory bowel disease that affects more than 1 million men and women worldwide. It has no cure and its cause is unknown.
| Wed, 09 Apr 2008 03:00:00 PDT
Omega-3's No Help For Crohn's Sufferers
An international study led by Dr. Brian Feagan of Robarts Research Institute at The University of Western Ontario in London, Canada has found that omega-3 fatty acids are ineffective for managing Crohn's disease. The research is published in the April 9 Journal of the American Medical Association.
| Tue, 08 Apr 2008 13:00:00 PDT
For Crohn's Patients, Omega-3 Fatty Acids Not Effective In Preventing Relapse
Administrationof omega-3 fatty acid supplements did not appear to improve the rate ofrelapse in patients with Crohn's disease, according to a study releasedon April 9, 2008 in JAMA. Crohn'sDisease is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.
|
Irritable Bowel Syndrome News
Mon, 12 May 2008 01:00:00 PDT
New NICE Guidelines Mean IBS Sufferers Will Be Tested For Coeliac Disease, UK
The symptoms of IBS and coeliac disease can often be very similar as a result the diagnosis of coeliac disease can be delayed or missed and IBS is misdiagnosed.
| Tue, 06 May 2008 01:00:00 PDT
Anti-depressants May Benefit Some Patients With Irritable Bowel Disease
Theories abound about the cause of Irritable Bowel Disease (IBD): Diet? Stress? Perhaps an infection? On the other hand, is it possible depression could be triggering the disease in some of the 20 per cent of Canadians suffering from this digestive system disorder? New research conducted by scientists in McMaster University's Intestinal Disease Research Program suggests it's highly likely that in some patients depression is wreaking havoc on the gut.
| Fri, 02 May 2008 00:00:00 PDT
Antidepressant Found To Alleviate Symptoms Of Irritable Bowel Syndrome In Adolescents
Researchers at Mattel Children's Hospital UCLA have found that low-dose antidepressant therapy can significantly improve the overall quality of life for adolescents suffering from irritable bowel syndrome, or IBS.The syndrome affects 6 percent of middle school students and 14 percent of high school kids in the United States.
| Wed, 30 Apr 2008 16:00:00 PDT
Sucampo Pharmaceuticals Obtains FDA Approval For AMITIZA(R) For The Treatment Of Irritable Bowel Syndrome With Constipation In Adult Women
Sucampo Pharmaceuticals, Inc., (NASDAQ: SCMP, Sucampo Pharmaceuticals) and Takeda Pharmaceutical Company Limited (TSE: 4502, Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S.
| Wed, 30 Apr 2008 03:00:00 PDT
FDA Approves Amitiza For IBS-C - Only Drug Available In USA For Irritable Bowel Syndrome With Constipation
The U.S. Food and Drug Administration approved Amitiza (lubiprostone) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women aged 18 and over. There is currently no prescription drug therapy for IBS-C. With this approval, Amitiza becomes the only FDA-approved medical treatment for IBS-C available in the United States. Irritable bowel syndrome is a disorder characterized by cramping, abdominal pain, bloating, constipation, and diarrhea.
|
|
